VivosRDGL +0.34% EV-to-FCF is -12.42 as of Jun. 27, 2026. The stock has 4 warning signs investors should review. Among 421 Medical Devices & Instruments companies, Vivos ranks worse than 237529.45% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vivos's Enterprise Value is $27.12 Mil.
Vivos's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.18 Mil. Therefore, Vivos's EV-to-FCF for today is -12.42.
The historical rank and industry rank for Vivos's EV-to-FCF or its related term are showing as below:
RDGL'
s EV-to-FCF Range Over the Past 10 Years
Min: -12.92 Med: -2.68 Max: -1.84
Current: -12.42
During the past 13 years, the highest EV-to-FCF of Vivos was -1.84. The lowest was -12.92. And the median was -2.68.
RDGL's EV-to-FCF is ranked worse than 100% of 421
companies
in the Medical Devices & Instruments industry
Industry Median: 22.82
vs RDGL: -12.42
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-06-27), Vivos's stock price is $0.0598.
Vivos's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.010. Therefore, Vivos's PE Ratio (TTM) for today is At Loss.
Vivos (OTCPK:RDGL) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vivos's share price for today is $0.0598.
Vivos's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vivos EV-to-FCF Related Terms
Vivos EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Vivos's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Vivos's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vivos's EV-to-FCF falls into.
Vivos's current Enterprise Value is $27.12 Mil.
Vivos's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivos (RDGL) has a EV-to-FCF of -12.42 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vivos and its competitors. According to the industry distribution chart, Vivos ranks #999999 out of 421 companies in the Medical Devices & Instruments industry.
Is Vivos' EV-to-FCF too high?
Vivos' current EV-to-FCF is -12.42. Based on the distribution chart, Vivos ranks #999999 out of 421 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Vivos' EV-to-FCF compare to FOFA and CODX?
According to the Medical Devices & Instruments industry distribution chart, Vivos ranks #999999 out of 421 companies for EV-to-FCF. This places Vivos in the lower half of its industry. The industry median EV-to-FCF is 22.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.82, based on 421 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vivos and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivos's current EV-to-FCF is -12.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos stock overvalued right now?
Vivos (RDGL) has a current EV-to-FCF of -12.42. The current EV-to-FCF is -12.42. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Vivos (RDGL), the current EV-to-FCF is -12.42 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivos Inc is a radiation oncology medical device company engaged in the development of its yttrium-90 (Y-90) based precision radionuclide therapy devices. Its portfolio includes RadioGel Precision Radionuclide Therapy (Human Division) for treating solid tumors and positive surgical margins in humans and IsoPet (Animal Division) for treating solid tumors in animals. Vivos also sells PLGA-g-PEG polymers and PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents. The company currently mainly operates in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDGL has been successfully added to your 